250 related articles for article (PubMed ID: 26521944)
1. Epigenetics in Brain Tumors: HDACs Take Center Stage.
Eyüpoglu IY; Savaskan NE
Curr Neuropharmacol; 2016; 14(1):48-54. PubMed ID: 26521944
[TBL] [Abstract][Full Text] [Related]
2. Quercetin modifies 5'CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells.
Kedhari Sundaram M; Hussain A; Haque S; Raina R; Afroze N
J Cell Biochem; 2019 Oct; 120(10):18357-18369. PubMed ID: 31172592
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic targeting in pancreatic cancer.
van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
[TBL] [Abstract][Full Text] [Related]
4. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.
Vahid F; Zand H; Nosrat-Mirshekarlou E; Najafi R; Hekmatdoost A
Gene; 2015 May; 562(1):8-15. PubMed ID: 25701602
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
6. [Aberrant expression of sox2 gene in malignant gliomas].
Volnitskiĭ AV; Semenova EV; Shtam TA; Kovalev RA; Filatov MV
Tsitologiia; 2014; 56(7):504-10. PubMed ID: 25696994
[TBL] [Abstract][Full Text] [Related]
7. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase Inhibitors in Cancer Therapy.
Sun Y; Sun Y; Yue S; Wang Y; Lu F
Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
[TBL] [Abstract][Full Text] [Related]
9. CpG island methylation and histone modifications: biology and clinical significance.
Esteller M
Ernst Schering Res Found Workshop; 2006; (57):115-26. PubMed ID: 16568952
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Treatment Options in Urothelial Carcinoma.
Pinkerneil M; Hoffmann MJ; Niegisch G
Methods Mol Biol; 2018; 1655():289-317. PubMed ID: 28889393
[TBL] [Abstract][Full Text] [Related]
11. New advances of microRNAs in glioma stem cells, with special emphasis on aberrant methylation of microRNAs.
Zhao B; Bian EB; Li J; Li J
J Cell Physiol; 2014 Sep; 229(9):1141-7. PubMed ID: 24374932
[TBL] [Abstract][Full Text] [Related]
12. Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells.
Sundaram MK; Ansari MZ; Al Mutery A; Ashraf M; Nasab R; Rai S; Rais N; Hussain A
Anticancer Agents Med Chem; 2018; 18(3):412-421. PubMed ID: 28925878
[TBL] [Abstract][Full Text] [Related]
13. Glioma epigenetics: From subclassification to novel treatment options.
Gusyatiner O; Hegi ME
Semin Cancer Biol; 2018 Aug; 51():50-58. PubMed ID: 29170066
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis.
Chen PJ; Huang C; Meng XM; Li J
Biochimie; 2015 Sep; 116():61-9. PubMed ID: 26116886
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of epigenetics regulation, prognostic and the correlation with immune infiltrates of GPX7 in adult gliomas.
Ferreira WAS; Vitiello GAF; da Silva Medina T; de Oliveira EHC
Sci Rep; 2022 Apr; 12(1):6442. PubMed ID: 35440701
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
18. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA; Orekhov AN; Bobryshev YV
Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
[TBL] [Abstract][Full Text] [Related]
19. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma.
Kim TY; Zhong S; Fields CR; Kim JH; Robertson KD
Cancer Res; 2006 Aug; 66(15):7490-501. PubMed ID: 16885346
[TBL] [Abstract][Full Text] [Related]
20. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
